Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.
Journal: NPJ breast cancer
Published: December 15, 2025
Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.
Journal: Journal of neuro-oncology
Published: November 25, 2025
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: September 09, 2025
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 26, 2024
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
Journal: Gynecologic oncology
Published: September 24, 2024
FT-4202, a selective pyruvate kinase R activator for sickle cell disease.
Journal: Experimental hematology
Published: March 25, 2024
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.
Journal: Nature cancer
Published: August 03, 2023
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Journal: Targeted oncology
Published: January 30, 2023
Prognostic factors of severe pneumonia in patients treated with rituximab in the intensive care unit.
Journal: The Journal of international medical research
Published: March 30, 2022
Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.
Journal: Gynecologic oncology
Published: March 29, 2022
Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 18, 2022
Last Updated: 09/26/2026